Independent fund research. Built on SEC filings.

How we research funds

Mutual fund · Small-Cap · Virtus

Virtus KAR Small-Mid Cap Growth Fund Class A (VAKSX)

Ticker VAKSX · Since 2020-12-08 · · Holdings as of Jun 30, 2026

Expense ratio
1.2%$120/yr per $10k
5-yr return
−0.9%annualized
1-yr return
−13.6%as of Dec 2025
Net assets
$6.4Mall share classes
Holdings
27

Bottom line

Is VAKSX a good fund? The bottom line

VAKSX is the Class A share class of Virtus KAR Small-Mid Cap Growth Fund, a managed small-cap mutual fund from Virtus.

Its expense ratio is 1.2% — about $120 a year on every $10,000 invested, more expensive than 70% of small-cap funds we track.

It returned −13.6% over one year, −0.9% a year over five years (as of Dec 31, 2025, per its prospectus).

With $6.4 million in net assets and 27 holdings, its largest position is West Pharmaceutical Services Inc (6.4%) and the top 10 make up 49.4% of the portfolio.

This share class carries a front-end sales charge of up to 5.5%; a no-load class or ETF alternative can avoid it.

What to watch

  • 5-year return in the bottom quarter of its category
  • Front-end sales load up to 5.5%
  • 12b-1 marketing fee of 0.25% a year
  • Small fund ($6.4 million) — small funds are likelier to close

Updated Nov 19, 2026

What VAKSX invests in

The fund has an investment objective of long-term capital appreication.

The fund pursues long-term capital appreciation in the small and medium market capitalization sectors while seeking to incur less risk than the small- and mid-cap growth markets. The fund invests in a select group of small and mid capitalization companies believed by the subadviser to possess sustainable competitive advantages at prices the subadviser deems attractive. The investment strategy emphasizes companies the subadviser believes to have a sustainable competitive advantage, strong management and low financial risk and to be able to grow over market cycles. Although the fund invests primarily in U.S. companies, it may invest in foreign securities and depositary receipts. Under normal circumstances, the fund invests at least 80% of its assets in common stocks of small- and mid-market capitalization companies. As of the date of this Prospectus, the funds subadviser considers small…

From the fund's prospectus (filed Jan 22, 2026).

VAKSX performance

Average annual total returns
1 yr5 yr10 yr
VAKSX−13.6%−0.9%—
Small-Cap median+7.6%+7.0%+9.2%

Source: Fund prospectus, as of Dec 31, 2025

Full VAKSX performance history →

What VAKSX costs

On a $10,000 investment, VAKSX's 1.2% expense ratio costs about $120 a year. The prospectus estimates $2,924 in total costs over 10 years (assuming 5% annual returns). The median small-cap fund charges 0.99%.

See the full VAKSX fee table →

VAKSX top 10 holdings

#Holding% of fund
1West Pharmaceutical Services Inc WST6.36%
2Hinge Health Inc HNGE6.03%
3Aaon Inc AAON5.43%
4Heico Corp HEI/A5.41%
5Teledyne Technologies Inc TDY4.83%
6Lemaitre Vascular Inc LMAT4.68%
7Ul Solutions Inc ULS4.22%
8Simpson Manufacturing Co Inc SSD4.22%
9Healthequity Inc HQY4.20%
10Sharkninja Inc SN3.96%

Source: SEC Form N-PORT, period ended Jun 30, 2026

The top 10 make up 49.4% of the fund. See all top 25 holdings and asset mix →

Alternatives to VAKSX

More funds like VAKSX →

VAKSX FAQ

What is the expense ratio of VAKSX?
VAKSX's expense ratio is 1.2%, which works out to about $120 a year for every $10,000 invested. The prospectus estimates total costs of $2,924 over 10 years on a $10,000 investment (assuming 5% annual returns).
Is VAKSX a good investment?
It depends on your goals, but the data points to: 5-year return in the bottom quarter of its category; front-end sales load up to 5.5%; 12b-1 marketing fee of 0.25% a year; small fund ($6.4 million) — small funds are likelier to close. This is general information, not personalized advice.
What does VAKSX hold?
VAKSX's largest holdings are West Pharmaceutical Services Inc (6.4%), Hinge Health Inc (6.0%), Aaon Inc (5.4%), Heico Corp (5.4%), Teledyne Technologies Inc (4.8%). It holds 27 positions in total as of Jun 30, 2026 (SEC Form N-PORT).
What is VAKSX's 5-year return?
VAKSX returned −0.9% a year over the five years ending Dec 31, 2025. Past performance does not guarantee future results.
Does VAKSX have a sales load?
Yes. VAKSX has a maximum front-end sales charge of 5.5%.
Who manages VAKSX?
VAKSX is offered by Virtus through Virtus Equity Trust.